Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Supriya Lifescience Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹850.10
High
₹894.35
Price Summary
| Previous Close | ₹861.35 |
|---|---|
| Day's Range | ₹850.10 - ₹894.35 |
| Open | ₹894.35 |
| 52 Week Range | ₹545.50 - ₹1,085.00 |
| Volume | 2,41,403 |
| Market Cap | ₹0.01 |
| Previous Close | ₹862.15 |
|---|---|
| Day's Range | ₹851.75 - ₹886.30 |
| Open | ₹885.95 |
| 52 Week Range | ₹545.65 - ₹1,085.50 |
| Volume | 18,130 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 2,084.04 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.12 |
| Price/Earning (TTM) | 34.98 |
| TTM EPS (₹) | 24.65 |
| P/E Ratio | 21.75 |
| Book Value(₹) | 5.68 |
| PAT Margin (%) | 22.86 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 25.30 |
| Trade Value ( ₹ in Lacs) | 156.63 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.12 |
| Price/Earning (TTM) | 34.98 |
| TTM EPS (₹) | 24.65 |
| P/E Ratio | 21.75 |
| Book Value(₹) | 5.68 |
| PAT Margin (%) | 22.86 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 25.30 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1450.74 | 6964.85 |
| Expenses | N/A | N/A |
| PBT | 474.12 | 2484.81 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 347.9 | 1879.58 |
About Supriya Lifescience Ltd.
| Founded | 2008 |
|---|---|
| Managing Director | Saloni Satish Wagh |
| NSE Symbol | SUPRIYA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,20,483.45 | 1,752.50 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,49,248.45 | 9,389.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,77,821.97 | 4,675.00 | 3,480.60 - 3,480.60 |
| Lenskart Solutions Ltd. | 1,13,750.62 | 656.45 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,11,241.63 | 1,115.20 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,10,239.70 | 7,667.00 | 6,696.50 - 6,696.50 |
| Laurus Labs Ltd. | 1,08,062.44 | 2,000.00 | 843.00 - 843.00 |
| Cipla Ltd. | 1,05,427.12 | 1,305.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 99,064.73 | 2,398.40 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 98,492.27 | 1,180.00 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
Sep
23
2026
Posted on Sep 23rd 2026
Supriya Lifescience informs about updates
Further to Letters dated July 4, 2026 and September 2, 2026, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that on partial development in the matter wherein, the Hon'ble Court of Law has vide its judgment dated September 22 , 2026 passed an order in relation to the Company's application for provisional release of a consignment of 200 kg of Ketamine Hydrochloride covered under Shipping Bill No. 3780061 dated June 2, 2026. The Hon'ble Court has allowed the Company's application for provisional release of the said goods, subject to deposit of ₹72 lakh with the Assistant Commissioner of Customs, Export, ACC, Mumbai-III within one week from the date of the order; Clarified that the authorities may continue adjudication and criminal proceedings in accordance with law; and clarified that it shall be open to the concerned officer to follow the procedure under Section 52A of the NDPS Act. The Company continues to monitor the matter and will duly inform the Stock Exchanges on any further development, including any order passed by the Hon’ble Court, as and when received by the Company, in accordance with the applicable regulatory requirements.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
23
2026
Posted on Jul 23rd 2026
Supriya Lifescience informs about newspaper advertisement
In terms of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that it enclosed copies of the newspaper advertisement extract for Postal Ballot Notice published in the newspapers, Financial Express (English Language) and Loksatta (Marathi Language).
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
8
2026
Posted on Oct 8th 2026
RPG Life Sciences informs about certificate
RPG Life Sciences has informed that it enclosed certificate dated October 03, 2026 issued by MUFG Intime India, Registrar and Transfer Agents, confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
8
2026
Posted on Oct 8th 2026
Viyash Scientific informs about allotment of equity shares
Viyash Scientific has informed that the Nomination and Remuneration Committee of the Company vide resolution passed by circulation on October 08, 2026, has approved the allotment of 1,35,880 equity shares of face value Rs. 2/- each, fully paid up, pursuant to the exercise of stock options under the Sequent Scientific Limited Employee Stock Option Plan 2020 (“Sequent ESOP 2020”) and the Viyash Scientific Limited Employee Stock Option Scheme 2026 (“Viyash ESOP 2026”), as detailed below: a. 79,000 equity shares at an exercise price of Rs. 86 per equity share to eligible optionees under Sequent ESOP 2020. b. 56,880 equity shares at an exercise price of Rs.101 per equity share to eligible optionees under Viyash ESOP 2026. The aforesaid equity shares shall rank pari passu in all respects with the existing equity shares of the Company. Consequent to the aforesaid allotment, the issued and paid-up equity share capital of the Company has increased from Rs. 88,32,55,340/- consisting of 44,16,27,670 Equity Shares of Rs. 2 each to Rs. 88,35,27,100, comprising of 44,17,63,550 Equity Shares of Rs. 2 each.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
8
2026
Posted on Oct 8th 2026
Fredun Pharmaceuticals informs about press release
Fredun Pharmaceuticals has informed that it enclosed press release titled ‘Fredun Pharmaceuticals Accelerates into a HighGrowth Branded Healthcare Platform’ Two Strategic Pet-Care Deals, Premium Wellness Launches, Capacity Expansion & Bonus Issue Position Company for the Next Leg of Growth issued by the company.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Supriya Lifescience Ltd. is ₹861.35 as of 2026-10-08.
The market capitalisation of Supriya Lifescience Ltd. is ₹6,938.82 as of 2026-10-08.
The 1-year return of Supriya Lifescience Ltd. is 145.80% as of 2026-10-08.
The P/E ratio of Supriya Lifescience Ltd. is 21.75 as of 2026-10-09.
The 52-week high and low of Supriya Lifescience Ltd. are ₹1,085.00 and ₹545.50, respectively, as of 2026-10-08.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
